-
Analytica executes agreement to acquire Brewer's Retractable Technologies
December 22, 2003
Analytica Limited (ASX:ALT) announces that it has executed an agreement with Brewer Retractable Technologies Pty Ltd ("Brewer") to acquire all intellectual property, including its patents and patent applications and related assets for Brewer's retractable technology. "An excellent opportunity for Analytica to acquire such superior medical technology", said Analytica's Managing Director Ron van der Pluijm.
-
Board of Directors invitation to Analytica shareholders to participate in Share Purchase Plan (SPP)
December 09, 2003
-
Fully underwritten Share Purchase Plan
December 08, 2003
Analytica Limited (ASX:ALT) announces a Share Purchase Plan (SPP) that offers existing shareholders an opportunity to purchase up to $5,000 in additional shares. The issue price of the new shares will be the greater of $0.08 or a 20 per cent discount to the weighted average price over the 5 days before the closing of the SPP. Since Analytica announced it will be executing the Memorandum of Understanding to acquire Brewer Retractable Technologies Pty Ltd on 26 November 2003, its shares have traded between 9.5 and 14.5 cents, with a weighted average trading price of 12.4 cents (calculation based on daily closing price).
-
Chairman's address to members of Analytica Ltd at the Annual General Meeting of the Company on 28 November 2003
November 28, 2003
-
Analytica assessing acquisition opportunity
November 26, 2003
Analytica Limited (ASX: ALT) today announced it has commenced negotiations to acquire Brewer Retractable Technologies ("Brewer"), a privately owned business specialising in the research and development of medical devices. Analytica and Brewer have executed a Memorandum of Understanding to this effect. Analytica is proposing to purchase all of Brewer's assets and intellectual property, including its patents and patent applications.
-
Review of operations for the quarter ending 30 September 2003 and Appendix 4C
October 31, 2003
Analytica's strategy is to grow through mergers and acquisitions of under performing trading businesses in the life sciences industry to create critical mass in this sector. In July the Company made a takeover bid for the listed medical device company SSH Medical Limited. Analytica subsequently withdrew this takeover bid when the Board of SSH proposed a debt funding facility for that company. Analytica's interest in SSH however remains.
-
Notice of Annual General Meeting
October 27, 2003
The Annual General Meeting of Analytica Limited ("Company") will be held at 10.00am on Friday, 28 November 2003 in the Gloucester Room at Quay West Suites, 98 Gloucester Street, The Rocks, Sydney, NSW 2000 Australia.
-
Appendix 4E and Annual Financial Report (for the year ended 30 June 2003)
September 12, 2003
TABLE OF CONTENTS
Corporate Information
Chairman's Letter
Director's Report
Corporate Governance Statement
Director's Declaration
Statement of Financial Performance
Statement of Financial Position
Statement of Cash Flows
Notes to the Financial Statements
Independant Audit Report
Shareholders Information
-
Analytica withdraws bid for SSH Medical Limited
September 10, 2003
On 22 July 2003 Analytica announced its intentions to make a takeover bid all of the shares in SSH Medical Limited ("SSH"). Analytica lodged its bidder's statement in ASIC and served the Bidders Statement on SSH.
-
Bidders Statement Lodged
August 22, 2003
Analytica Ltd today lodged its Bidders Statement for the takeover of SSH Medical Limited with ASIC and served a copy on SSH Medical Ltd.
-
Appendix 3B - New Issue Announcement
August 06, 2003
-
Analytica comments on SSH's appendix 4C and alternative funding
August 01, 2003
On 24 July 2003 SSH Medical Limited (SSH) released an ASX announcement in response to Analytica's takeover proposal. In that release SSH advises its shareholders that it has been (and is) exploring a potential capital raising as an alternative to Analytica's takeover bid. Analytica believed this to be misleading and nothing more than an attempt by the CEO and the Board to mislead shareholders into thinking that the supposed capital raising is a credible alternative to the Analytica bid. On 28 July 2003 called on SSH to substantiate this claim. SSH replied to Analytica on 30 July 2003. The effect of its reply is that it is unwilling and/or unable to substantiate this claim.
-
Review of operations for the quarter ending 30 June 2003 and Appendix 4C
July 31, 2003
When Analytica acquired its diagnostic business from Psiron Ltd in December 2001 it did so to create a trading business in the life sciences sector. Analytica's strategy is to grow through mergers and acquisitions of similar businesses to create critical mass in this sector, and was commenced with the recently announced takeover offer for SSH Medical.
-
Takeover offer for SSH Medical and financial restructure
July 22, 2003
This announcement by Analytica Ltd sets out some major developments in the strategy of the Company to take the Company forward as a consolidator of the medical and biotechnology industry in Australia. Analytica is also announcing a financial restructure so it can give effect to this strategy.
-
Notice of change of interest of substantial holder
July 22, 2003
-
Analytica enters into contract manufacturing alliance with Rockeby Biomed
July 07, 2003
Analytica Ltd has executed a Memorandum of Understanding with biotechnology company, Rockeby Biomed Ltd, for the contract manufacture of their diagnostic ELISA test for candidiasis, SyScan 3.
-
Annual Financial Report for the Year Ended 30 June 2003
September 12, 2003
-
Analytica launches two new products
June 25, 2003
Today biotechnology company Analytica Ltd announced that it has launched a further two new products developed by its in-house R & D department.
-
Review of quarter ended 31 March, 2003 and Appendix 4C
April 29, 2003
In the third financial quarter of this financial year Analytica's performance was in line withexpectations. Sales of our diagnostic products were equal to sales in the same quarter of the previous year. The first two new products developed by our internal R&D department are currently under review by the pathology labs. Another three new products are expected to be launched before the end of this financial year.
-
Appendix 4B - Half Yearly/Preliminary Final Report
March 11, 2003
-
Response to ASX questions relating to the Company's December 2002 Appendix 4C.
February 04, 2003
-
Analytica continues to perform
January 28, 2003
In the second financial quarter of this financial year, Analytica continued to perform in line with its strategic plan. Sales of our diagnostic products were in line with budget and the first two new products developed in our internal R&D department were launched in December.
-
Analytica executes sub-licence agreement with US diagnostic company for its Gluten test
January 09, 2003
Biotechnology company Analytica Ltd announced that it has executed a sub-license agreement with a US diagnostic company for its gluten test kit. This test is based on a unique antibody and is used to detect gluten content in food. Analytica has an exclusive worldwide licence from the CSIRO to the patents and know-how for this test. Under the agreement Analytica sub-licenses the know-how and patents to the US company and the US company will pay an annual fee and purchase the antibodies from Analytica. ?An excellent agreement?, said Ron van der Pluijm, Analytica's Chief Executive. ?Our first direct entry into the US market, with a very well respected US Company?. Gluten intolerance is increasing around the world and having a unique method of identifying the gluten content in food, positions us perfectly in this market. For further information, please contact: Ron van der Pluijm Managing Director Analytica Ltd 02 9659 8652
